Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model
A Kieffer, M Beuvelet, A Sardesai… - The Journal of …, 2022 - academic.oup.com
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting …
United States, especially among infants. Nirsevimab, an investigational long-acting …
Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static …
A Kieffer, M Beuvelet, A Sardesai, R Musci… - The Journal of …, 2022 - europepmc.org
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting …
United States, especially among infants. Nirsevimab, an investigational long-acting …
Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static …
A Kieffer, M Beuvelet, A Sardesai… - The Journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting …
United States, especially among infants. Nirsevimab, an investigational long-acting …
Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model.
A Kieffer, M Beuvelet, A Sardesai, R Musci, S Milev… - 2022 - cabidigitallibrary.org
Background: Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting …
United States, especially among infants. Nirsevimab, an investigational long-acting …
[HTML][HTML] Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A …
A Kieffer, M Beuvelet, A Sardesai, R Musci… - The Journal of …, 2022 - ncbi.nlm.nih.gov
Background Respiratory syncytial virus (RSV) is associated with substantial morbidity in the
United States, especially among infants. Nirsevimab, an investigational long-acting …
United States, especially among infants. Nirsevimab, an investigational long-acting …